Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer Therapies02:49

Cancer Therapies

10.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Blood Rheology After Allogeneic Hematopoietic Stem Cell Transplantation or Gene Therapy in Sickle Cell Disease.

Blood advances·2026
Same author

Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis.

Frontiers in immunology·2026
Same author

Donor lymphocyte infusions after HCT are associated with low risk of graft-versus-host disease in pediatric and young adult patients.

Blood immunology & cellular therapy·2026
Same author

Author Correction: cBAF complex components and MYC cooperate early in CD8<sup>+</sup> T cell fate.

Nature·2026
Same author

Costimulation drives CAR-T cell division fate.

Nature immunology·2026
Same author

Successful autologous T cell apheresis in pediatric patients with hematologic malignancies, solid tumors, and brain tumors.

Cytotherapy·2026

Related Experiment Video

Updated: Feb 20, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K

Cell therapy for brain tumors: The first 60 years.

Sanya Mehta1, Giedre Krenciute2, Stephen Gottschalk2

  • 1Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, TN 38105, USA; Graduate School of Biomedical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

Cell Reports. Medicine
|February 18, 2026
PubMed
Summary

Cellular immunotherapies, including T cells and natural killer cells, show promise for treating primary brain tumors. Early studies demonstrate safety and durable responses, especially when combined with other treatments.

More Related Videos

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

18.6K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Related Experiment Videos

Last Updated: Feb 20, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

22.1K
Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting
08:14

Processing of Primary Brain Tumor Tissue for Stem Cell Assays and Flow Sorting

Published on: September 25, 2012

18.6K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.5K

Area of Science:

  • Neuro-oncology
  • Immunology
  • Cancer Research

Background:

  • Primary brain tumors are highly lethal cancers with limited treatment options.
  • Immunotherapy offers a promising avenue to overcome current treatment limitations.

Purpose of the Study:

  • To provide a historical review of cellular immunotherapies for brain tumors.
  • To summarize clinical experience and key findings from published studies.

Main Methods:

  • Review of early-phase clinical trials since the late 1960s.
  • Analysis of various cellular immunotherapy approaches tested in brain tumor patients.

Main Results:

  • Early studies using nonspecific leukocytes, PBMCs, and bone marrow cells showed safety and occasional durable responses.
  • Subsequent approaches included LAK cells, TILs, ex vivo expanded T cells, NK cells, and CAR T cells.

Conclusions:

  • Adoptive cell therapies have evolved significantly over six decades.
  • Cellular immunotherapies demonstrate potential for brain tumor treatment, particularly in combination or upfront settings.